INSM Insmed Inc

Standard & Poor�s announced today that it has commenced Factual Stock Report coverage on Insmed, Inc. Insmed, Inc. (NASDAQ:INSM) is a biopharmaceutical company focused on the development and commercialization of drugs to treat metabolic diseases and endocrine disorders within niche markets that have unmet medical needs. The company's development and commercial activities are focused on drugs that modulate Insulin-like Growth Factor-1 (IGF-1) activity in the human body. Its lead product, IPLEX, is the only FDA approved, once-daily IGF-1 replacement therapy. IPLEX was approved in December 2005 for the treatment of growth failure in children with severe primary IGF-1 deficiency or with growth hormone gene deletion who have developed neutralizing antibodies to growth hormone. As an Orphan Drug, IPLEX is entitled to seven years of marketing exclusivity in the treatment of Severe Primary IGFD in the U.S. This report will also be accessible on an ongoing basis to a wide audience of the investment community ---- scores of buy-side institutions and sell-side firms that utilize S&P research and information platforms daily. Millions of self-directed investors also have access to the report via their e-brokerage accounts. About Standard & Poor�s Factual Stock Reports This S&P service provides factual research coverage enabling companies to reach a wide investor audience of Buy and Sell-side investors, helping them understand the fundamentals and business prospects. Many of these companies are not widely covered by Wall Street analysts. Currently profiling over 1,000 issuers, S&P Factual Stock Reports increase market awareness for companies in the investment community with insightful commentary and key statistics/information. Updated weekly with the latest pricing, trading volume and other data, the reports include recent developments, an income statement analysis and financial review, key operating information, performance charts, business summary, fundamental data, industry and peer comparisons, institutional holdings analysis, Street Consensus and opinions, and news. Because coverage of these reports is sponsored by the issuer, S&P does not offer investment opinions concerning the advisability of investing in these stocks. Standard & Poor�s Factual Stock Reports are produced separately from any other analytic activity of Standard & Poor�s. Standard & Poor�s Factual Report research has no access to non-public information received by other units of Standard & Poor�s. Standard & Poor�s does not trade on its own account. Note: All U.S. and Canadian Companies listed on a National Exchange (not covered by S&P�s STARS research) are eligible to obtain this coverage. About Standard & Poor's Standard & Poor's, a division of The McGraw-Hill Companies (NYSE:MHP), is the world�s foremost provider of independent credit ratings, indices, risk evaluation, investment research, data and valuations. With approximately 6,300 employees located in 20 countries and markets, Standard & Poor's is an essential part of the world�s financial infrastructure and has played a leading role for more than 140 years in providing investors with the independent benchmarks they need to feel more confident about their investment and financial decisions. For more information, visit http://www.standardandpoors.com.